McGuire Investment Group LLC Decreases Holdings in IQVIA Holdings Inc. (NYSE:IQV)

McGuire Investment Group LLC lowered its position in IQVIA Holdings Inc. (NYSE:IQV) by 0.2% in the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 59,413 shares of the medical research company’s stock after selling 115 shares during the period. IQVIA comprises about 1.7% of McGuire Investment Group LLC’s investment portfolio, making the stock its 23rd biggest holding. McGuire Investment Group LLC’s holdings in IQVIA were worth $11,675,000 at the end of the most recent reporting period.

A number of other hedge funds also recently bought and sold shares of the company. Capital Performance Advisors LLP bought a new position in shares of IQVIA in the 3rd quarter worth approximately $27,000. Park Place Capital Corp bought a new position in IQVIA in the third quarter worth approximately $28,000. Avior Wealth Management LLC boosted its stake in shares of IQVIA by 117.6% during the 3rd quarter. Avior Wealth Management LLC now owns 161 shares of the medical research company’s stock worth $38,000 after acquiring an additional 87 shares during the last quarter. Assetmark Inc. grew its position in shares of IQVIA by 612.5% during the 3rd quarter. Assetmark Inc. now owns 228 shares of the medical research company’s stock valued at $54,000 after acquiring an additional 196 shares during the period. Finally, UMB Bank n.a. increased its stake in shares of IQVIA by 74.4% in the 3rd quarter. UMB Bank n.a. now owns 232 shares of the medical research company’s stock worth $55,000 after purchasing an additional 99 shares in the last quarter. Hedge funds and other institutional investors own 89.62% of the company’s stock.

IQVIA Price Performance

IQVIA stock opened at $204.54 on Friday. IQVIA Holdings Inc. has a 52-week low of $187.62 and a 52-week high of $261.73. The company has a market cap of $37.12 billion, a price-to-earnings ratio of 26.84, a PEG ratio of 2.14 and a beta of 1.48. The firm’s fifty day moving average is $199.47 and its 200 day moving average is $221.09. The company has a quick ratio of 0.81, a current ratio of 0.81 and a debt-to-equity ratio of 1.76.

Analyst Upgrades and Downgrades

IQV has been the topic of several analyst reports. Robert W. Baird lowered their target price on IQVIA from $212.00 to $210.00 and set a “neutral” rating on the stock in a research report on Tuesday. Leerink Partners reiterated an “outperform” rating and set a $248.00 price objective (down from $260.00) on shares of IQVIA in a research note on Tuesday, November 19th. William Blair reaffirmed an “outperform” rating on shares of IQVIA in a report on Wednesday, December 11th. Deutsche Bank Aktiengesellschaft decreased their price objective on shares of IQVIA from $270.00 to $265.00 and set a “buy” rating on the stock in a research report on Friday, November 1st. Finally, Redburn Atlantic started coverage on shares of IQVIA in a report on Monday, October 14th. They issued a “buy” rating and a $276.00 target price for the company. Four equities research analysts have rated the stock with a hold rating, seventeen have issued a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat, IQVIA has an average rating of “Moderate Buy” and an average price target of $255.71.

IQVIA Profile

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.